Sit in your designated dosing spot
Not intended to diagnose, treat, cure, or prevent disease
Discontinuation of therapy due to adverse events across treatment groups was 3.0%, 2.8%, and 2.9% for placebo, empagliflozin 10 mg, and empagliflozin 25 mg, respectively
Endocrinology 141 , 111117 (2000)
Meta-analyses of these and other studies have demonstrated: Reductions in total cholesterol typically in the range of 15% from baseline, varying by agent and population Decreases in LDL cholesterol ranging from 17%, generally more modest than dedicated lipid-lowering therapies Reductions in triglycerides of 515%, with greater effects often seen in those with higher baseline levels Variable effects on HDL cholesterol , with small increases (1-2%) or neutral effects reported The magnitude of lipid improvements appears to correlate with the degree of weight loss achieved, suggesting that metabolic benefits may be partially mediated through adiposity reduction
Any microdosing approach should be supervised by a licensed healthcare provider who can monitor your response, adjust dosing, and watch for complications
